11.04.2011 • NewsDaniel VasellaNovartisAlcon

Novartis Eyes Debts, Possible Smaller Buys

Swiss drugmaker Novartis will focus on its debts before undertaking any big purchases following its acquisition of eyecare group Alcon, Novartis's chairman was quoted as saying on Saturday.

The Basel-based firm spent much of last year trying to clinch 100% ownership of Alcon and has finally sealed its $50.9 billion buy by paying Alcon's minority shareholders an extra $463 million in cash.

"Now it's about cutting back on the debt burden somewhat before we can undertake new big buys," Chairman Daniel Vasella told Swiss newspaper Blick. "But smaller bolt-ons are surely still possible in the near future."

Vasella, who previously served as the firm's chief executive, also said the Alcon buy was expected to yield synergies of more than $300 million in the next three years.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Virtual Event

DIGITALIZATION IN THE CHEMICAL INDUSTRY

DIGITALIZATION IN THE CHEMICAL INDUSTRY

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.